| Michael Harris Nathanson, MD | |
|
15 York St, Lmp - 180, New Haven, CT 06510-3221 | |
| (203) 785-4138 | |
| (203) 737-1345 |
| Full Name | Michael Harris Nathanson |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 39 Years |
| Location | 15 York St, New Haven, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437132230 | NPI | - | NPPES |
| 001293654 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 029365 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Bridgeport Hospital | Bridgeport, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yale University | 9436061736 | 2241 |
News Archive
As announced on November 17, 2010, certain members (the "Petitioning Creditors") of the Ad Hoc Group of Vitro Noteholders (the "Ad Hoc Noteholder Group"), comprised of holders, or investment advisors to holders, of the Senior Notes due 2012, 2013 and 2017 (collectively, the "Senior Notes") issued by Vitro S.A.B. de C.V. ("Vitro"), commenced involuntary bankruptcy cases (the "Cases") under chapter 11 of the U.S. Bankruptcy Code against fifteen of Vitro's U.S. subsidiary guarantors (the "U.S. Subsidiary Debtors").
Sirtex today unveiled a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining increasingly wide acceptance worldwide.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.
The Mediterranean diet is back in the news again and for all the right reasons.
› Verified 5 days ago
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
As announced on November 17, 2010, certain members (the "Petitioning Creditors") of the Ad Hoc Group of Vitro Noteholders (the "Ad Hoc Noteholder Group"), comprised of holders, or investment advisors to holders, of the Senior Notes due 2012, 2013 and 2017 (collectively, the "Senior Notes") issued by Vitro S.A.B. de C.V. ("Vitro"), commenced involuntary bankruptcy cases (the "Cases") under chapter 11 of the U.S. Bankruptcy Code against fifteen of Vitro's U.S. subsidiary guarantors (the "U.S. Subsidiary Debtors").
Sirtex today unveiled a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining increasingly wide acceptance worldwide.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.
The Mediterranean diet is back in the news again and for all the right reasons.
› Verified 5 days ago
| Entity Name | Bridgeport Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649260845 PECOS PAC ID: 2062312598 Enrollment ID: O20040120000425 |
News Archive
As announced on November 17, 2010, certain members (the "Petitioning Creditors") of the Ad Hoc Group of Vitro Noteholders (the "Ad Hoc Noteholder Group"), comprised of holders, or investment advisors to holders, of the Senior Notes due 2012, 2013 and 2017 (collectively, the "Senior Notes") issued by Vitro S.A.B. de C.V. ("Vitro"), commenced involuntary bankruptcy cases (the "Cases") under chapter 11 of the U.S. Bankruptcy Code against fifteen of Vitro's U.S. subsidiary guarantors (the "U.S. Subsidiary Debtors").
Sirtex today unveiled a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining increasingly wide acceptance worldwide.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.
The Mediterranean diet is back in the news again and for all the right reasons.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Harris Nathanson, MD 15 York St, Lmp - 180, New Haven, CT 06510-3221 Ph: (203) 785-4138 | Michael Harris Nathanson, MD 15 York St, Lmp - 180, New Haven, CT 06510-3221 Ph: (203) 785-4138 |
News Archive
As announced on November 17, 2010, certain members (the "Petitioning Creditors") of the Ad Hoc Group of Vitro Noteholders (the "Ad Hoc Noteholder Group"), comprised of holders, or investment advisors to holders, of the Senior Notes due 2012, 2013 and 2017 (collectively, the "Senior Notes") issued by Vitro S.A.B. de C.V. ("Vitro"), commenced involuntary bankruptcy cases (the "Cases") under chapter 11 of the U.S. Bankruptcy Code against fifteen of Vitro's U.S. subsidiary guarantors (the "U.S. Subsidiary Debtors").
Sirtex today unveiled a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining increasingly wide acceptance worldwide.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.
The Mediterranean diet is back in the news again and for all the right reasons.
› Verified 5 days ago
Dr. Brian Christopher Cambi, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 333 Cedar St, Dcb 3, New Haven, CT 06510 Phone: 203-785-4129 Fax: 203-737-2437 | |
Ms. Maryam Gondal, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 330 Cedar Street, Bb 114, New Haven, CT 06510 Phone: 203-785-4184 | |
Matthew Joseph Mcconnell, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 333 Cedar St, Ynhh Internal Medicine-gi,section Of Digestive Diseases, New Haven, CT 06510 Phone: 203-785-7012 | |
Marie Anjeliese Rodriguez, Gastroenterology Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Dr. Margaret M Xu, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Carola Marte, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1450 Chapel St, Haelen Center, New Haven, CT 06511 Phone: 203-789-4135 Fax: 203-867-5241 | |
Jeanette M Tetrault, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Long Wharf Dr, New Haven, CT 06511 Phone: 203-781-4600 Fax: 203-781-4624 |